🇺🇸 non-pegylated liposomal doxorubicin in United States

26 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaemia — 3 reports (11.54%)
  2. Bone Lesion — 3 reports (11.54%)
  3. Cytopenia — 3 reports (11.54%)
  4. Disease Progression — 3 reports (11.54%)
  5. Electrocardiogram Repolarisation Abnormality — 3 reports (11.54%)
  6. Febrile Neutropenia — 3 reports (11.54%)
  7. Ejection Fraction Abnormal — 2 reports (7.69%)
  8. Malignant Neoplasm Progression — 2 reports (7.69%)
  9. Off Label Use — 2 reports (7.69%)
  10. Pancytopenia — 2 reports (7.69%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is non-pegylated liposomal doxorubicin approved in United States?

non-pegylated liposomal doxorubicin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for non-pegylated liposomal doxorubicin in United States?

GBG Forschungs GmbH is the originator. The local marketing authorisation holder may differ — check the official source linked above.